What changed from existing technology?
This study looked at why some patients with heart failure and weak heart function didn't reach a specific treatment goal during hospitalization.
This is the first study to analyze the specific clinical factors that prevent patients from reaching a strict GDMT target during hospitalization for HFrEF.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
deline-directed medical therapy target at discharge in patients with HFrEF undergoing scheduled hospitalization: a secondary analysis of the HEROES study. Gui
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study could help identify patients at risk of not achieving optimal GDMT during hospitalization, allowing for targeted interventions.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.